Related references
Note: Only part of the references are listed.The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Evolving therapies for liver fibrosis
Detlef Schuppan et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling
Yuqing Liu et al.
LIVER INTERNATIONAL (2013)
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo
Ki Cheong Park et al.
CANCER SCIENCE (2011)
Epigenetic Repression of Matrix Metalloproteinases in Myofibroblastic Hepatic Stellate Cells through Histone Deacetylases 4 Implication in Tissue Fibrosis
Lan Qin et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Histone Deacetylase Inhibition Suppresses the Transforming Growth Factor β1-Induced Epithelial-to-Mesenchymal Transition in Hepatocytes
Aki Kaimori et al.
HEPATOLOGY (2010)
Fibrogenesis in Pediatric Cholestatic Liver Disease: Role of Taurocholate and Hepatocyte-Derived Monocyte Chemotaxis Protein-1 in Hepatic Stellate Cell Recruitment
Grant A. Ramm et al.
HEPATOLOGY (2009)
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor
Dong Hoon Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis
J. Mann et al.
CELL DEATH AND DIFFERENTIATION (2007)
Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans
E. Novo et al.
GUT (2006)
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
AM Elsharkawy et al.
APOPTOSIS (2005)
被撤回的出版物: Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2 (Retracted article. See vol. 295, pg. 294, 2020)
K Yamaguchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis
E Borkham-Kamphorst et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
The role of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type I collagen expression
S Reif et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor
K Rombouts et al.
JOURNAL OF HEPATOLOGY (2002)
NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines
JD Cheng et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma
XBX Cao et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
SL Friedman
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
